Sanofi invests $700 million in genetic medicines

Sanofi’s subsidiary Genzyme has expanded its partnership with Alnylam Pharmaceuticals to develop drugs for rare genetic diseases.

The $700 million investment will give Genzyme/Sanofi a 12 per cent share of Alnylam, and access to its drug candidates – for example, its phase 2 familial amyloid cardiomyopathy treatment.


“This new relationship with Genzyme is transformational for Alnylam.
“It is a game-changer for both the advancement of RNAi therapeutics as a new class of genetic medicines to patients around the world, and for our commitment to build a leading, independent biopharmaceutical company that delivers value to our shareholders.
“In this new alliance, Alnylam benefits enormously from Genzyme’s proven global capabilities, enabling us to accelerate and expand market access for our ‘Alnylam 5×15’ products.”
John Maraganore, chief executive, Alnylam.


Related news:

Sanofi pays $700 million for Alnylam drugs and stake (Bloomberg).

Sanofi to buy 12 percent of Alnylam, expands rare-disease drug deal (Reuters).

Reference link:

Genzyme and Alnylam expand collaboration on rare genetic diseases (Sanofi press release).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.